Xifaxan rifaximin regulatory update

FDA accepted for filing and granted Priority Review to an sNDA from Salix for Xifaxan rifaximin 550 mg tablets to treat non-constipation irritable bowel syndrome (IBS) and IBS-related bloating. The PD...